The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Dengvaxia Market Change Between 2026 And 2030?
The dengvaxia market size has shown significant expansion in recent years. Its valuation is set to increase from $213.36 million in 2025 to $250.81 million in 2026, achieving a compound annual growth rate (CAGR) of 17.6%. The market’s past growth can be ascribed to elements such as repeated dengue outbreaks, a considerable disease burden in tropical climates, immunization campaigns led by governments, limited therapeutic choices for dengue, and heightened public health understanding.
The dengvaxia market is projected to experience substantial expansion in the coming years, reaching $473.95 million in 2030 at a compound annual growth rate (CAGR) of 17.2%. This anticipated growth during the forecast period is propelled by factors such as broader vaccination coverage, the increasing spread of mosquitoes due to climate change, enhanced public health funding, better vaccine delivery systems, and a growing demand for travel-related immunizations. Key developments during this period are expected to encompass the expansion of dengue vaccination initiatives, a heightened emphasis on preventing endemic diseases, an increase in public health immunization drives, more robust surveillance of mosquito-borne illnesses, and reinforced vaccination efforts for children and adolescents.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20035&type=smp
Which Core Factors Are Supporting The Expansion Of The Dengvaxia Market?
The dengvaxia market is anticipated to expand due to the significant occurrence of dengue. This viral ailment, spread by Aedes mosquitoes, manifests with flu-like symptoms, intense pain, and can progress to severe, life-threatening conditions like dengue hemorrhagic fever or dengue shock syndrome. The growing spread of dengue can be attributed to factors such as climate shifts, increased urbanization, more travel, and larger mosquito breeding sites, which together lead to higher infection rates and a greater need for both prevention and treatment. Dengvaxia offers protection against dengue by acting as an effective vaccine that prompts the immune system to mount a defensive reaction against the virus, thereby lowering the chances of infection and severe health issues, and enhancing public health in regions where the disease is common. For example, in June 2024, the Centers for Disease Control and Prevention (CDC), a US-based government agency, indicated that the Americas recorded more than 9.7 million dengue cases, which is twice the 4.6 million cases reported in 2023. Puerto Rico announced a public health emergency due to 1,498 cases, and 745 cases were documented among U.S. travelers. Consequently, the elevated incidence of dengue is propelling the growth within the dengvaxia market.
Dengvaxia Market Driver: Impact Of Rising International Travel On Market Growth
The dengvaxia market is projected to expand with the increase in international travel. International travel involves journeys undertaken between different nations for activities such as tourism, business, or educational pursuits. A surge in global mobility heightens the potential for infectious diseases, including dengue, to spread, thereby stimulating the need for preventative solutions like vaccines. Dengvaxia serves a crucial role amidst increasing international travel by safeguarding individuals journeying to regions where dengue is prevalent and by minimizing the inter-country transmission of the disease. For instance, in May 2024, data from the Office for National Statistics, a UK-based government department, revealed that international visits to the UK significantly climbed from 31.2 million in 2022 to 38.0 million in 2023. Consequently, the uptick in international travel will contribute to the growth of the dengvaxia market.
Which Segment Divisions Form The Structure Of The Dengvaxia Market?
The dengvaxia market covered in this report is segmented –
1) By Type: Dengvaxia, Other Types
2) By Distribution Channel: Hospitals, Clinics, Public Health Programs
3) By Clinical Indication: Prevention In Previously Infected Individuals, Protection In High-Risk Regions, Traveler Immunization, Pediatric And Adolescent Use
Who Are The Companies Shaping The Dengvaxia Market Landscape?
Major companies operating in the dengvaxia market are Sanofi Pasteur Inc.
Access The Complete Dengvaxia Market Report:
https://www.thebusinessresearchcompany.com/report/dengvaxia-global-market-report
Which Region Holds The Largest Share In The Dengvaxia Market?
Asia-Pacific was the largest region in the dengvaxia market in 2025. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengvaxia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model